Join us and learn about the scientific data supporting Surefire at the CIRSE Scientific Symposium Saturday, September 26, 2015 from 13:00-14:00 in Auditorium 2
Improved Tumor Coverage
in Cancers of the Liver
48-year-old patient with HCC. Quantitative analysis shows a 67% increase with the Surefire in larger superior mass. Clinical results published in JVIR.
Reduced procedure time in secondary liver cancer procedures.
J. D. Louie et al., Stanford University Medical Center, “In chemoembolization patients, completion C-arm CT imaging suggested a pattern of increased microsphere tumor penetration and contrast retention”, March 2012.
Study shows Surefire Infusion System achieving 99.9% embolization efficiency versus 72% in a standard microcatheter, Dec. 2012.